Cargando…
YAP/TAZ Activation as a Target for Treating Metastatic Cancer
Yes-Associated Protein (YAP) and Transcriptional Co-activator with PDZ-binding Motif (TAZ) have both emerged as important drivers of cancer progression and metastasis. YAP and TAZ are often upregulated or nuclear localized in aggressive human cancers. There is abundant experimental evidence demonstr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923370/ https://www.ncbi.nlm.nih.gov/pubmed/29642615 http://dx.doi.org/10.3390/cancers10040115 |
_version_ | 1783318326300114944 |
---|---|
author | Warren, Janine S. A. Xiao, Yuxuan Lamar, John M. |
author_facet | Warren, Janine S. A. Xiao, Yuxuan Lamar, John M. |
author_sort | Warren, Janine S. A. |
collection | PubMed |
description | Yes-Associated Protein (YAP) and Transcriptional Co-activator with PDZ-binding Motif (TAZ) have both emerged as important drivers of cancer progression and metastasis. YAP and TAZ are often upregulated or nuclear localized in aggressive human cancers. There is abundant experimental evidence demonstrating that YAP or TAZ activation promotes cancer formation, tumor progression, and metastasis. In this review we summarize the evidence linking YAP/TAZ activation to metastasis, and discuss the roles of YAP and TAZ during each step of the metastatic cascade. Collectively, this evidence strongly suggests that inappropriate YAP or TAZ activity plays a causal role in cancer, and that targeting aberrant YAP/TAZ activation is a promising strategy for the treatment of metastatic disease. To this end, we also discuss several potential strategies for inhibiting YAP/TAZ activation in cancer and the challenges each strategy poses. |
format | Online Article Text |
id | pubmed-5923370 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-59233702018-05-03 YAP/TAZ Activation as a Target for Treating Metastatic Cancer Warren, Janine S. A. Xiao, Yuxuan Lamar, John M. Cancers (Basel) Review Yes-Associated Protein (YAP) and Transcriptional Co-activator with PDZ-binding Motif (TAZ) have both emerged as important drivers of cancer progression and metastasis. YAP and TAZ are often upregulated or nuclear localized in aggressive human cancers. There is abundant experimental evidence demonstrating that YAP or TAZ activation promotes cancer formation, tumor progression, and metastasis. In this review we summarize the evidence linking YAP/TAZ activation to metastasis, and discuss the roles of YAP and TAZ during each step of the metastatic cascade. Collectively, this evidence strongly suggests that inappropriate YAP or TAZ activity plays a causal role in cancer, and that targeting aberrant YAP/TAZ activation is a promising strategy for the treatment of metastatic disease. To this end, we also discuss several potential strategies for inhibiting YAP/TAZ activation in cancer and the challenges each strategy poses. MDPI 2018-04-10 /pmc/articles/PMC5923370/ /pubmed/29642615 http://dx.doi.org/10.3390/cancers10040115 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Warren, Janine S. A. Xiao, Yuxuan Lamar, John M. YAP/TAZ Activation as a Target for Treating Metastatic Cancer |
title | YAP/TAZ Activation as a Target for Treating Metastatic Cancer |
title_full | YAP/TAZ Activation as a Target for Treating Metastatic Cancer |
title_fullStr | YAP/TAZ Activation as a Target for Treating Metastatic Cancer |
title_full_unstemmed | YAP/TAZ Activation as a Target for Treating Metastatic Cancer |
title_short | YAP/TAZ Activation as a Target for Treating Metastatic Cancer |
title_sort | yap/taz activation as a target for treating metastatic cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923370/ https://www.ncbi.nlm.nih.gov/pubmed/29642615 http://dx.doi.org/10.3390/cancers10040115 |
work_keys_str_mv | AT warrenjaninesa yaptazactivationasatargetfortreatingmetastaticcancer AT xiaoyuxuan yaptazactivationasatargetfortreatingmetastaticcancer AT lamarjohnm yaptazactivationasatargetfortreatingmetastaticcancer |